Characteristics of patients undergoing hemodialysis who received BNT162b2 and mRNA-1273 COVID-19 vaccines
| Characteristic | No. (%) of hemodialysis patients* | p value | |
|---|---|---|---|
| BNT162b2 vaccine n = 129 | mRNA-1273 vaccine n = 95 | ||
| Age, yr; median (IQR) | 72 (62–79) | 62 (55–67) | < 0.001 |
| Male sex | 88 (68.2) | 70 (73.7) | 0.4 |
| Previous COVID-19† | 6 (4.6) | 5 (5.3) | 1.00 |
| Days between doses, median (IQR) | 26 (21–35) | 30 (30–31) | < 0.001 |
| Comorbidity | |||
| Prior solid-organ transplant | 5 (4.0) | 28 (29.5) | < 0.001 |
| Immunosuppressive treatment‡ | 10 (7.7) | 17 (17.9) | 0.02 |
| Diabetes mellitus | 72 (55.8) | 33 (34.7) | 0.002 |
| Coronary artery disease | 52 (40.3) | 14 (14.7) | < 0.001 |
| Congestive heart failure | 35 (27.1) | 21 (22.1) | 0.4 |
| Cerebrovascular disease | 17 (13.2) | 9 (9.5) | 0.4 |
| Hypertension | 121 (93.7) | 84 (88.4) | 0.15 |
Note: IQR = interquartile range.
↵* Unless stated otherwise.
↵† Confirmed by reverse transcription–polymerase chain reaction at study enrolment.
↵‡ Defined as taking any of the following: antimetabolite agent, calcineurin inhibitor, cytotoxic medications, rituximab in the previous 6 months, tumour necrosis factor α-monoclonal antibodies, glucocorticoids at a dosage of more than prednisone 5 mg daily or active chemotherapy.